| scholarly article | Q13442814 |
| P50 | author | Osaro Erhabor | Q56811378 |
| P2093 | author name string | T C Adias | |
| P2860 | cites work | The evaluation and management of platelet refractoriness and alloimmunization | Q30305594 |
| Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. | Q30826863 | ||
| The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q31114479 | ||
| Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology | Q33336231 | ||
| Guidelines for the use of platelet transfusions | Q33348675 | ||
| Component therapy | Q33356933 | ||
| Optimizing platelet transfusion therapy | Q33361167 | ||
| Relationship between platelet count and bleeding risk in thrombocytopenic patients | Q33361658 | ||
| Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama | Q33363313 | ||
| Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients | Q33364823 | ||
| Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients | Q33370872 | ||
| First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat | Q33378373 | ||
| Subcutaneous anti-D globulin application is a safe treatment option of immune thrombocytopenia in children | Q33386606 | ||
| Appropriate hospital management of adult immune thrombocytopenic purpura patients in major Italian institutions in 2000-2002: a retrospective analysis | Q33386804 | ||
| Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia | Q33387173 | ||
| Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions | Q33501221 | ||
| Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study | Q33521097 | ||
| Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis | Q33869859 | ||
| The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. | Q34551456 | ||
| Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology | Q34946830 | ||
| Clinical practice guideline: red blood cell transfusion in adult trauma and critical care | Q35004615 | ||
| Red cell freezing and its impact on the supply chain | Q35714186 | ||
| Prevalence and outcomes of anemia in cancer: a systematic review of the literature | Q35721774 | ||
| Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis | Q36190634 | ||
| Haemophilia B: Christmas disease | Q36221979 | ||
| Transfusion immunomodulation or TRIM: what does it mean clinically? | Q36270091 | ||
| A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. | Q36492560 | ||
| The use of fresh whole blood in massive transfusion | Q36501118 | ||
| Fresh whole blood transfusion: a controversial military practice | Q36532895 | ||
| Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery | Q36588876 | ||
| Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature | Q36923137 | ||
| Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review | Q36945945 | ||
| Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency | Q36968194 | ||
| Evidence-based platelet transfusion guidelines | Q37007307 | ||
| Warfarin reversal in anticoagulant-associated intracerebral hemorrhage | Q37063465 | ||
| A prospective audit program to determine blood component transfusion appropriateness at a large university hospital: a 5-year experience | Q37114155 | ||
| Warm fresh whole blood transfusion for severe hemorrhage: U.S. military and potential civilian applications | Q37204741 | ||
| Pathogen reduction of blood components | Q37207560 | ||
| Management of excessive anticoagulant effect due to vitamin K antagonists | Q37346734 | ||
| Treatment of congenital fibrinogen deficiency: overview and recent findings | Q37388583 | ||
| Correction of coagulopathy in warfarin associated cerebral hemorrhage | Q37418713 | ||
| Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings | Q37511511 | ||
| Effect of early plasma transfusion on mortality in patients with ruptured abdominal aortic aneurysm | Q37727584 | ||
| Long-term storage of peripheral blood stem cells frozen and stored with a conventional liquid nitrogen technique compared with cells frozen and stored in a mechanical freezer | Q43242600 | ||
| Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy | Q44504515 | ||
| An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B. | Q45855778 | ||
| Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B. | Q45858960 | ||
| Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients | Q45869222 | ||
| The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series | Q45883934 | ||
| Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors | Q45885613 | ||
| Fluid therapy and the use of albumin in the treatment of severe traumatic brain injury | Q46302647 | ||
| Impact of plasma transfusion in massively transfused trauma patients | Q46722289 | ||
| The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery | Q50116315 | ||
| Transfusion therapy in postpartum hemorrhage. | Q50614451 | ||
| Risk factors for postoperative infections in patients with hip fracture treated by means of Thompson arthroplasty. | Q50617898 | ||
| Standardization of the red cell product. | Q50740968 | ||
| Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. | Q51618206 | ||
| When is an albumin infusion needed? | Q52082835 | ||
| Survey of the use of whole blood in current blood transfusion practice. | Q52862018 | ||
| Fresh whole blood transfusions in coalition military, foreign national, and enemy combatant patients during Operation Iraqi Freedom at a U.S. combat support hospital. | Q53226045 | ||
| Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. | Q53784097 | ||
| The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States. | Q54087056 | ||
| Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant | Q56675460 | ||
| PrP expression in B lymphocytes is not required for prion neuroinvasion | Q57083708 | ||
| Recommendations for the Management of Intracranial Haemorrhage – Part I: Spontaneous Intracerebral Haemorrhage | Q61649811 | ||
| Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-β and prostaglandin E2 | Q61699944 | ||
| Massive obstetric haemorrhage | Q73732992 | ||
| Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions | Q77497220 | ||
| Residual WBC subsets in filtered prestorage RBCs | Q78766976 | ||
| Guidelines on the management of massive blood loss | Q79361874 | ||
| Both infiltrating regulatory T cells and insufficient antigen presentation are involved in long-term cardiac xenograft survival | Q80641664 | ||
| Platelet transfusion therapy | Q80709486 | ||
| The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease | Q83524449 | ||
| A survey of physicians' reasons to transfuse plasma and platelets in the critically ill: a prospective single-centre cohort study | Q84463266 | ||
| P433 | issue | 5-6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Sub-Saharan Africa | Q132959 |
| whole blood | Q7997549 | ||
| P304 | page(s) | 516-526 | |
| P577 | publication date | 2011-10-28 | |
| P1433 | published in | Transfusion Clinique et Biologique | Q15758506 |
| P1476 | title | From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa | |
| P478 | volume | 18 |
| Q44720659 | A study of blood transfusion services at a district hospital in Malawi |
| Q35598919 | Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak |
| Q90829025 | The global need and availability of blood products: a modelling study |
| Q30235022 | The ongoing evolution of antibody-based treatments for Ebola virus infection |
| Q36789989 | Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection |
Search more.